Oncopeptides to host a Capital Markets Day in New York on December 14th
A detailed program will be published in beginning of December.
For further information, please contact:
Rein Piir, Head of Investor Relations at Oncopeptides AB
RSVP to Alan Lada at firstname.lastname@example.org
This information was submitted for publication at 10.30 CET October 25, 2018
Oncopeptides is a pharmaceutical company developing drugs for the treatment of cancer. The company is focusing on the development of the lead product candidate Ygalo®, an alkylating peptide, belonging to a new class of drugs (Peptidase Enhanced Compounds – PEnCs). Ygalo® is intended as an effective treatment of hematological cancers, and in particular multiple myeloma. The goal with the current clinical study program is to demonstrate better results from treatment with Ygalo® compared with established alternative drugs for patients with late-stage multiple myeloma. Ygalo® will potentially provide physicians with a new treatment option for patients suffering from this serious disease.
Visit www.oncopeptides.se for more information.